A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer

被引：24

作者：

Nixon, N. A. ^{[1
]}

Hannouf, M. B. ^{[2
,3
]}

Verma, S. ^{[1
]}

机构：

[1] Univ Calgary, Cumming Sch Med, Dept Oncol, 1331 29th St NW, Calgary, AB T2N 4N2, Canada

[2] Western Univ, Schulich Sch Med & Dent, Dept Epidemiol & Biostat, London, ON, Canada

[3] Western Univ, Ivey Sch Business, London, ON, Canada

来源：

EUROPEAN JOURNAL OF CANCER | 2018年 / 89卷

关键词：

Value; Cost-effectiveness; Human epidermal growth factor receptor-2 (HER2); Breast cancer; COST-EFFECTIVENESS ANALYSIS; ADJUVANT TRASTUZUMAB THERAPY; LAPATINIB PLUS CAPECITABINE; PHASE-III TRIAL; MONOCLONAL-ANTIBODY; ECONOMIC-EVALUATION; OPEN-LABEL; HER2; CHEMOTHERAPY; PERTUZUMAB;

D O I：

10.1016/j.ejca.2017.10.037

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The cost of cancer drugs continues to escalate with the rapid development and approval of novel therapies, especially over the course of the last decade. In human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the survival benefits gained by new treatments have been undeniably substantial. It is important to assess the financial value of these therapies for decision making at both the societal and individual level. This information is key for managing resources in resource-limited health care systems, while at the same time supporting patient decision-making and conversations between patient and physicians on cost versus benefit. In this article, we perform a systematic review of cost-effectiveness analyses that have been completed to date on HER2-targeted agents, focussing on those that correlate with standard of care therapy. Our discussion also highlights potential strategies to overcome several limitations associated with measuring value for anticancer drugs. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：72 / 81

页数：10

共 68 条

[11] Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective [J].

Clarke, Caroline S. ;

Hunter, Rachael M. ;

Shemilt, Ian ;

Serra-Sastre, Victoria .

PLOS ONE, 2017, 12 (03)

[12] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[13] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response [J].

de Azambuja, Evandro ;

Holmes, Andrew P. ;

Piccart-Gebhart, Martine ;

Holmes, Eileen ;

Di Cosimo, Serena ;

Swaby, Ramona F. ;

Untch, Michael ;

Jackisch, Christian ;

Lang, Istvan ;

Smith, Ian ;

Boyle, Frances ;

Xu, Binghe ;

Barrios, Carlos H. ;

Perez, Edith A. ;

Azim, Hatem A., Jr. ;

Kim, Sung-Bae ;

Kuemmel, Sherko ;

Huang, Chiun-Sheng ;

Vuylsteke, Peter ;

Hsieh, Ruey-Kuen ;

Gorbunova, Vera ;

Eniu, Alexandru ;

Dreosti, Lydia ;

Tavartkiladze, Natalia ;

Gelber, Richard D. ;

Eidtmann, Holger ;

Baselga, Jose .

LANCET ONCOLOGY, 2014, 15 (10) :1137-1146

[14] Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial [J].

Dedes, K. J. ;

Szucs, T. D. ;

Imesch, P. ;

Fedier, A. ;

Fehr, M. K. ;

Fink, D. .

ANNALS OF ONCOLOGY, 2007, 18 (09) :1493-1499

[15] Cost-effectiveness of lapatinib plus capecitabine in women with HER2+metastatic breast cancer who have received prior therapy with trastuzumab [J].

Delea, Thomas E. ;

Tappenden, Paul ;

Sofrygin, Oleg ;

Browning, Dominy ;

Amonkar, Mayur M. ;

Karnon, Jon ;

Walker, Mel D. ;

Cameron, David .

EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2012, 13 (05) :589-603

[16] Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer [J].

Durkee, Ben Y. ;

Qian, Yushen ;

Pollom, Erqi L. ;

King, Martin T. ;

Dudley, Sara A. ;

Shaffer, Jenny L. ;

Chang, Daniel T. ;

Gibbs, Iris C. ;

Goldhaber-Fiebert, Jeremy D. ;

Horst, Kathleen C. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) :902-+

[17] Targeting PI3K signalling in cancer: opportunities, challenges and limitations [J].

Engelman, Jeffrey A. .

NATURE REVIEWS CANCER, 2009, 9 (08) :550-562

[18] Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands [J].

Essers, Brigitte A. B. ;

Seferina, Shanley C. ;

Tjan-Heijnen, Vivianne C. G. ;

Severens, Johan L. ;

Novak, Annoesjka ;

Pompen, Marjolein ;

Oron, Ulrich H. ;

Joore, Manuela A. .

VALUE IN HEALTH, 2010, 13 (04) :375-380

[19]

Fagnani F, 2007, B CANCER, V94, P711

[20] Economic foundations of cost-effectiveness analysis [J].

Garber, AM ;

Phelps, CE .

JOURNAL OF HEALTH ECONOMICS, 1997, 16 (01) :1-31

← 1 2 3 4 5 6 7 →